New Drug Pricing Bills Will Improve Competition, Help End Big Pharma Gaming, And Drive Down Costs For Consumers

posted by AHIP

on April 4, 2019

WASHINGTON, D.C. – Matt Eyles, President, and CEO of America’s Health Insurance Plans (AHIP), issued this statement today following the approval of several bipartisan bills in the House Energy & Commerce Committee, including the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act and pay-for-delay amendment. These bills were introduced by Chairman Frank Pallone (D-NJ) and Representative Greg Walden (R-OR):

Every American deserves access to the medications they need at a price they can afford. With drug prices out of control, we need legislative changes to increase market competition and sustainably lower drug prices and costs for everyone.

We thank Chairman Pallone and Representative Walden for their bipartisan support of the CREATES Act and the pay-for-delay amendment. For too long, drug makers have exploited the system for their own financial gain, blocking competition, preventing generics from getting approved, and raising drug prices year over year. These bills are a significant step forward in driving competition and closing loopholes, making medications and premiums more affordable for Americans.

We join the Administration and members of Congress in their commitment to bring down drug prices and hold drug makers accountable for their anti-competitive strategies. No one should have to choose between innovation and affordability – with these types of solutions and collaboration we can have both.”

" "